Eylea Global Market Report 2024

The eylea market size has grown strongly in recent years. It will grow from $7.8 billion in 2023 to $8.19 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period for Eylea can be attributed to several factors. These include the prevalence of diabetic macular edema (DME), the demonstrated clinical efficacy and safety profile of Eylea, competition with other anti-VEGF therapies (vascular endothelial growth factor inhibitors), approvals for treating various retinal conditions, and a notable shift in the treatment approach towards intravitreal injections for retinal disorders. These factors collectively contributed to the demand and growth of Eylea in the historic period.

The eylea market size is expected to see strong growth in the next few years. It will grow to $10.16 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period for Eylea can be attributed to several factors. These include the emergence of new therapeutic indications, the introduction of biosimilar competition in the market, a rise in awareness and diagnosis of relevant conditions, the importance of real-world evidence and post-market studies, and a growing preference among patients for less frequent injections. Major trends expected in this period include advancements in imaging technologies for more accurate diagnosis and monitoring, the increasing role of telemedicine and remote monitoring in eye care, the implementation of patient assistance programs, continuous advances in drug delivery technologies, innovations in retinal imaging technologies, and the conduct of clinical trials exploring new indications for Eylea. These trends collectively contribute to the evolving landscape of Eylea in the forecast period.

The expansion of the Eylea market is being driven by the increasing prevalence of ocular diseases, which encompasses various eye conditions hindering proper eye function and impacting vision clarity. Eylea, a treatment addressing ocular diseases such as wet age-related macular degeneration (AMD) and glaucoma, works by impeding the protein responsible for the growth of weakened blood vessels and reducing retina swelling caused by vessel blockages. As of October 2022, reports from the BrightFocus Foundation estimated around 80 million global cases of glaucoma, expected to surpass 111 million by 2040. This upsurge in ocular diseases is a key driver for the growing demand for Eylea.

The anticipated growth of the Eylea market is attributed to the rising global geriatric population, generally aged 65 and above. This demographic shift significantly contributes to the increasing prevalence of conditions treated by Eylea, as older individuals are at a higher risk of developing ocular diseases. Statistics from the World Health Organization in October 2022 predicted a considerable rise in the global population aged 60 and above, projecting an increase from 1 billion in 2020 to approximately 1.4 billion by 2022. This trend is expected to continue, with estimates indicating that by 2030, 1 in 6 people globally will be aged 60 or older. Hence, this demographic shift is a major catalyst driving the expansion of the Eylea market.

A prominent trend in the Eylea market involves extensive research and development efforts aimed at innovative solutions. Key players, such as Regeneron Pharmaceuticals, Inc., are committed to pioneering technical advancements in Eylea. In August 2023, Regeneron Pharmaceuticals secured approval from the US FDA for Eylea HD (aflibercept) injection 8 mg. This approval extends Eylea's application to treat patients with wet AMD, diabetic macular edema (DME), and diabetic retinopathy (DR). The treatment regimen involves an initial phase of injections every four weeks for three months across all indications, followed by adjusted intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy. This signifies the industry's dedication to evolving treatment strategies and enhancing patient care through continual research and development initiatives.

Major players in the eylea market are strategically focusing on the development of biologic medications, specifically biosimilars akin to aflibercept, to secure a competitive edge within the industry. Aflibercept Biosimilars represent biologically comparable iterations of the reference drug aflibercept, engineered to exhibit no clinically significant disparities and offer a cost-efficient substitute for treating certain eye-related conditions. For instance, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical company, secured marketing authorization from the European Commission (EC) for YESAFILI, a biosimilar version of Aflibercept, within the European Union (EU). The EC's endorsement, following a favorable review by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July, signifies YESAFILI's compatibility in quality, safety, and efficacy with the reference product Eylea (aflibercept). YESAFILI is specifically designed as an ophthalmological treatment for various eye conditions.

In January 2023, Coherus BioSciences Inc., a US-based biopharmaceutical entity, acquired exclusive commercialization rights to the Eylea Biosimilar Candidate from Klinge Biopharma GmbH for $32.5 million. This acquisition underscores Coherus BioSciences' commitment to expanding treatment options and improving access for both physicians and patients seeking high-quality and affordable alternatives to anti-VEGF therapies across the healthcare spectrum. Klinge Biopharma GmbH, a Germany-based pharmaceutical company, specializes in providing ocular disease drugs such as Eylea Biosimilar. This strategic move allows Coherus BioSciences to fortify its portfolio in offering alternative treatments while expanding its market reach in ocular care.

Major companies operating in the eylea market report are Regeneron Pharmaceuticals Inc., Bayer AG, Santen Pharmaceutical Co Ltd, Momenta Pharmaceuticals Inc., Novartis AG, Mylan NV, Vertex Pharmaceuticals Incorporated, Alvotech Switzerland AG, Sanofi SA, F Hoffmann-La Roche AG, PV Pharma, Alteogen Inc., Viatris Inc., Biocon Biologics Limited, Nexus Lifecare Pvt Ltd, AbbVie Inc., Alcon Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Amgen Inc., Apotex Inc., Aurobindo Pharma Ltd., Lupin Ltd., Biogen Inc., Bristol-Myers Squibb Company, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Merck & Co. Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC.

North America was the largest region in the eylea market in 2023. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eylea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main packaging formats for Eylea include prefilled syringe packages and vial packages. Prefilled syringe packages are disposable syringes that come pre-loaded with the drug, streamlining the administration process. Eylea is employed in the treatment of conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and other disorders. These medications are typically distributed through hospitals, retail pharmacies, and other healthcare applications.

The eylea market research report is one of a series of new reports that provides eylea market statistics, including eylea industry global market size, regional shares, competitors with an eylea market share, detailed eylea market segments, market trends and opportunities, and any further data you may need to thrive in the eylea industry. This eylea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.